[davidnicholsoncron]

You’re right to be cautious about new biosimilar drugs, especially with something as essential as insulin. Just like with HGH—which has strict testing and approval processes due to its direct effects on the body—insulin biosimilars go through extensive testing. The FDA requires that biosimilars show they’re safe, effective, and practically identical to the original. Any new insulin product has to prove itself through rigorous trials.

For injected drugs like insulin (and HGH), the manufacturer also needs specific approvals for safe delivery. The FDA monitors this process closely, and yes, they’ll make parts of the clinical data publicly available. So your concerns are understandable, but these safety nets are in place to make sure any new biosimilar works as well as the original.

If you’re interested in learning more about the safety measures for HGH, this article has useful information: HGH Replacement Therapy Side Effects.